190 related articles for article (PubMed ID: 34598060)
41. [Research advancement and prospects of nanotechnology in early diagnosis and treatment of cancer].
Hu DH; Gong P; Ma YF; Cai LT
Ai Zheng; 2009 Sep; 28(9):1000-3. PubMed ID: 19728922
[TBL] [Abstract][Full Text] [Related]
42. Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology.
Jokar N; Velikyan I; Ahmadzadehfar H; Rekabpour SJ; Jafari E; Ting HH; Biersack HJ; Assadi M
Clin Nucl Med; 2021 Aug; 46(8):e410-e420. PubMed ID: 34152118
[TBL] [Abstract][Full Text] [Related]
43. Brave new world revisited: Focus on nanomedicine.
Fadeel B; Alexiou C
Biochem Biophys Res Commun; 2020 Nov; 533(1):36-49. PubMed ID: 32921412
[TBL] [Abstract][Full Text] [Related]
44. Nanotheranostics for personalized medicine.
Kim TH; Lee S; Chen X
Expert Rev Mol Diagn; 2013 Apr; 13(3):257-69. PubMed ID: 23570404
[TBL] [Abstract][Full Text] [Related]
45. Omics-based nanomedicine: the future of personalized oncology.
Rosenblum D; Peer D
Cancer Lett; 2014 Sep; 352(1):126-36. PubMed ID: 23941830
[TBL] [Abstract][Full Text] [Related]
46. Polyvalent Nanoobjects for Precision Diagnostics.
Omstead DT; Sjoerdsma J; Bilgicer B
Annu Rev Anal Chem (Palo Alto Calif); 2019 Jun; 12(1):69-88. PubMed ID: 30811215
[TBL] [Abstract][Full Text] [Related]
47. Chimeric aptamers in cancer cell-targeted drug delivery.
Kanwar JR; Roy K; Kanwar RK
Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150
[TBL] [Abstract][Full Text] [Related]
48. Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer.
Dolatkhah M; Hashemzadeh N; Barar J; Adibkia K; Aghanejad A; Barzegar-Jalali M; Omidi Y
Colloids Surf B Biointerfaces; 2020 Sep; 193():111104. PubMed ID: 32417466
[TBL] [Abstract][Full Text] [Related]
49. Nano Metal Based Herbal Theranostics for Cancer Management: Coalescing Nature's Boon with Nanotechnological Advancement.
Pandey Y; Ambwani S
Curr Pharm Biotechnol; 2022; 23(1):30-46. PubMed ID: 33480341
[TBL] [Abstract][Full Text] [Related]
50. Recognition of G-quadruplex topology through hybrid binding with implications in cancer theranostics.
Suseela YV; Satha P; Murugan NA; Govindaraju T
Theranostics; 2020; 10(23):10394-10414. PubMed ID: 32929356
[TBL] [Abstract][Full Text] [Related]
51. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
52. Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
Int J Pharm; 2020 Jan; 573():118729. PubMed ID: 31705975
[TBL] [Abstract][Full Text] [Related]
53. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
Ozeki T; Tagami T
Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
[TBL] [Abstract][Full Text] [Related]
54. Inorganic nanoparticles for predictive oncology of breast cancer.
Yezhelyev M; Yacoub R; O'Regan R
Nanomedicine (Lond); 2009 Jan; 4(1):83-103. PubMed ID: 19093898
[TBL] [Abstract][Full Text] [Related]
55. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
Schaefer N; Prior J
Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
[TBL] [Abstract][Full Text] [Related]
56. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
57. Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.
Jiang M; Yang J; Li K; Liu J; Jing X; Tang M
Int J Med Sci; 2021; 18(3):626-638. PubMed ID: 33437197
[TBL] [Abstract][Full Text] [Related]
58. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy.
Jhawat V; Gulia M; Gupta S; Maddiboyina B; Dutt R
J Control Release; 2020 Nov; 327():500-511. PubMed ID: 32858073
[TBL] [Abstract][Full Text] [Related]
59. Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics.
de Sousa Cunha F; Dos Santos Pereira LN; de Costa E Silva TP; de Sousa Luz RA; Nogueira Mendes A
J Drug Target; 2019 Aug; 27(7):732-741. PubMed ID: 30207742
[TBL] [Abstract][Full Text] [Related]
60. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
